M. Samama

发表

Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients

R. Yusen, A. Turpie, M. Monreal, 2013, Thrombosis and Haemostasis.

Evaluation of a method to assess red blood cell aggregation.

M. Samama, A. Chabanel, 1989, Biorheology.

Laboratory Diagnosis of the Thrombophilic State in Cancer Patients

M. Samama, I. Gouin-Thibault, M. Samama, 1999, Seminars in thrombosis and hemostasis.

Low molecular weight heparin in prevention of perioperative thrombosis.

J. Boissel, F. Chapuis, M. Samama, 1992, BMJ.

Venous thromboembolism (VTE) in Europe

E. Oger, J. Heit, A. Cohen, 2007, Thrombosis and Haemostasis.

Acute Ischemic Stroke and Heparin Treatments

M. Bousser, M. Samama, P. Desnoyers, 1997, Thrombosis and Haemostasis.

Thrombolytic Therapy

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Prophylaxis of venous thromboembolism in medical patients

M. Samama, G. Gerotziafas, M. Samama, 2004, Current opinion in pulmonary medicine.

Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy.

M. Samama, J. Seghatchian, 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Original Article: Streptokinase Modifies in Vitro Platelet Aggregation by Two Mechanisms: Reduced Aggregation due to Fibrinogenolysis and Enhanced Aggregation via an Immunological Reaction.

G. Helft, M. Samama, T. Lecompte, 1995, Platelets.

Coagulation Assays in Patients with New Oral Anticoagulants (NOACs): Why? When?

M. Samama, 2013 .

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.

C. Samama, S. Susen, P. Fontana, 2013, Archives of cardiovascular diseases.

Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.

M. Samama, P. Mismetti, N. Rosencher, 2003, Haematologica.

Effects of long travels in sitting position in elderly volunteers on biological markers of coagulation activation and fibrinolysis.

J. Bertrand, M. Samama, B. Tardy, 1996, Thrombosis research.

Prevention and Treatment of Venous and Arterial Thrombosis in Patients with Specific Conditions: Diabetes, Hypercoagulable States, Pregnancy, and Renal Insufficiency

M. Samama, J. Conard, G. Gerotziafas, 2012 .

New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

J. Hirsh, M. Samama, J. Weitz, 2004, Chest.

Heparin-Induced Thrombocytopenia

G. Raskob, A. Nicolaides, M. Griffin, 2013, Thrombosis and Haemostasis.

Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin

M. Samama, I. Elalamy, G. Gerotziafas, 2009, Thrombosis and Haemostasis.

In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide.

M. Samama, I. Elalamy, F. Rendu, 2008, Thrombosis research.

An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients

M. Samama, F. Kleber, 2006, Thrombosis journal.

A European view on the North American fifth consensus on antithrombotic therapy.

M. Verstraete, M. Samama, R. Verhaeghe, 2000, Chest.

Treatment for Patients With Cancer

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Diagnosis and Anticoagulant Treatment *

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Key Questions to be Answered

G. Raskob, A. Nicolaides, M. Griffin, 2013 .

[Non-VKA oral anticoagulants: an update for the clinical biologists].

J. Dogné, M. Samama, I. Gouin-Thibault, 2015, Annales de biologie clinique.

In vitro aspirin resistance detected by PFA‐100TM closure time: pivotal role of plasma von Willebrand factor

M. Samama, I. Elalamy, G. Gerotziafas, 2004, British journal of haematology.

Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.

M. Samama, I. Elalamy, G. Gerotziafas, 2012, Thrombosis research.

Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls

M. Samama, E. Perzborn, T. Spiro, 2011, Thrombosis and Haemostasis.

Laboratory assessment of rivaroxaban: a review

M. Samama, E. Perzborn, T. Spiro, 2013, Thrombosis Journal.

Ultraviolet irradiation of platelet concentrates: feasibility in transfusion practice

M. Oleggini, M. Samama, G. Andreu, 1990, Transfusion.

Ex vivo reversal of the anticoagulant effects of edoxaban.

M. Samama, J. Mendell, A. Halim, 2014, Thrombosis research.

Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood

F. Depasse, M. Samama, I. Elalamy, 2004, Thrombosis and Haemostasis.

Assays for Measuring Rivaroxaban: Their Suitability and Limitations

T. Ortel, M. Samama, J. Weitz, 2010, Therapeutic drug monitoring.

PL2‐49, a monoclonal antibody against glycoprotein IIb which is a platelet activator

M. Samama, T. Lecompte, R. Favier, 1989, British journal of haematology.

Human Anti-Streptokinase Antibodies Induce Platelet Aggregation in an Fc Receptor (CD32) Dependent Manner

G. Helft, M. Samama, T. Lecompte, 1995, Thrombosis and Haemostasis.

Monitoring plasma levels of factor Xa inhibitors: how, why and when?

J. Amiral, M. Samama, J. Seghatchian, 2013, Expert review of hematology.

Interindividual variability of in vitro response to anticoagulants.

M. Samama, 2011, Thrombosis research.

Pharmacokinetics of low molecular weight heparins.

M. Samama, L. Bara, 1988, Acta chirurgica Scandinavica. Supplementum.

Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage.

M. Haugh, M. Samama, A. Leizorovicz, 1993, Haemostasis.

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.

M. Samama, J. Fareed, W. Jeske, 1997, Thrombosis research.

Effect of the anti‐factor Xa and anti‐factor IIa activities of low‐molecular‐weight heparins upon the phases of thrombin generation

M. Samama, I. Elalamy, G. Gerotziafas, 2007, Journal of thrombosis and haemostasis : JTH.

Haemostatic variables and menopausal status: influence of hormone replacement therapy.

L. Guize, C. Bonithon-Kopp, M. Samama, 1993 .

The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia

M. Samama, T. Lecompte, I. Elalamy, 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets.

M. Samama, I. Elalamy, M. Abdelouahed, 1997, Thrombosis research.

Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP.

M. Samama, T. Lecompte, R. Favier, 1990, Thrombosis research.

Calcium rise in human platelets elicited by anti-CD9 and -CD41 murine monoclonal antibodies.

M. Samama, T. Lecompte, R. Favier, 1989, Thrombosis research.

Characterization of an anti-IIb/IIIa monoclonal antibody which is a platelet activator.

M. Samama, T. Lecompte, R. Favier, 1988, Current studies in hematology and blood transfusion.

Relationship between plasminogen activator inhibitor activity and menopausal status

L. Guize, C. Bonithon-Kopp, M. Samama, 1990 .

Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action "Clotart".

H. Prydz, G. Mariani, F. Bernardi, 1999, Haematologica.

Intra-Coronary Thrombolysis with Streptokinase or Lys-Plasminogen/Urokinase in Acute Myocardial Infarction: Effects on Recanalization and Blood Fibrinolysis

C. Guérot, M. Samama, M. Horellou, 1983, Thrombosis and Haemostasis.

ANTITHROMBOTIC ACTIVITY OF A SYNTHETIC HEPARIN PENTASACCHARIDE IN A RABBIT STASIS THROMBOSIS MODEL USING DIFFERENT THROMBOGENIC CHALLENGES

M. Samama, J. Fareed, M. Petitou, 1987, Thrombosis and Haemostasis.

Inferior Vena Cava Filters

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation.

M. Samama, I. Gouin-Thibault, I. Elalamy, 2002, Thrombosis research.

Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency.

R. Bertina, K. Bauer, R. Rosenberg, 1988, Blood.

Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency.

J. Griffin, A. Gruber, K. Bauer, 1993, Blood.

Afibrinogenemia resulting from homozygous nonsense mutation in A alpha chain gene associated with multiple thrombotic episodes

P. de Mazancourt, M. Samama, H. Erdem, 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices.

F. Depasse, L. Sensébé, M. Samama, 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

New Data on the Pharmacology of Heparin and Low Molecular Weight Heparins

M. Samama, I. Gouin-Thibault, L. Bara, 2012, Drugs.

The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma.

M. Samama, L. Bara, A. Bendetowicz, 1990, Thrombosis research.

Haemorrhagic aspects of thrombolytic therapy.

M. Samama, 1990, European heart journal.

On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma

F. Depasse, M. Samama, I. Elalamy, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life‐threatening haemorrhage: focus on prothrombin activation

M. Samama, G. Gerotziafas, K. Zervas, 2002, British journal of haematology.

Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study

M. Samama, C. Guinet, L. L. Flem, 2013, Journal of Thrombosis and Thrombolysis.

Synthetic direct and indirect factor Xa inhibitors.

M. Samama, 2002, Thrombosis research.

Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model.

M. Samama, J. Fareed, M. Petitou, 1986, Thrombosis research.

Streptokinase and APSAC Inhibit Platelet Aggregation In Vitro by Fibrinogenolysis: Effect of Plasma Fibrinogen Degradation Products X and E

M. Samama, T. Lecompte, M. Mirshahi, 1995 .

Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study.

A. Evans, D. Arveiler, G. Luc, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Lowmolecular weight heparin inprevention ofperioperative thrombosis

M. Samama, M. CHaugh, 1992 .

Clinical Studies with Low Molecular Weight Heparins in the Prevention and Treatment of Venous Thromboembolism

M. Samama, J. Boissel, A. Leizorovicz, 1989, Annals of the New York Academy of Sciences.

M. Samama, J. Conard, P. Scarabin, 1988, Clinical science.

Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility

E. Vicaut, R. Yusen, A. Turpie, 2010, Annals of Internal Medicine.

An electronic tool for venous thromboembolism prevention in medical and surgical patients.

J. Kahan, M. Samama, P. Mismetti, 2006, Haematologica.

Contemporary laboratory monitoring of low molecular weight heparins.

M. Samama, L. Poller, 1995, Clinics in laboratory medicine.

Platelest counting: visual, electronic and fully automated optical methods.

M. Samama, C. Capelle, A. Beuzart, 1972, Advances in experimental medicine and biology.

Familial Dysfibrinogenemia and Thrombophilia

M. Samama, F. Haverkate, 1995, Thrombosis and Haemostasis.

Clinical Aspects and Laboratory Problems in Hereditary Thrombophilia

M. Samama, M. Horellou, I. Elalamy, 1999, Pathophysiology of Haemostasis and Thrombosis.

Occurrence of thrombosis and haemorrhage, relationship with anti‐Xa, anti‐IIa activities, and D‐dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery

M. Samama, A. Planès, L. Bara, 1999, British journal of haematology.

Absence of In Vitro Cross-Reaction of Pentasaccharide with the Plasma Heparin-Dependent Factor of Twenty-Five Patients with Heparin-Associated Thrombocytopenia

M. Samama, I. Elalamy, J. Marie, 1995, Thrombosis and Haemostasis.

Screening for aspirin resistance in stable coronary artery patients by three different tests.

M. Samama, I. Elalamy, H. Gamra, 2007, Thrombosis research.

Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.

F. Chédru, M. Bousser, M. Samama, 1996, Stroke.

Étude de la variabilité de réponse à l ’ aspirine et au clopidogrel : résistance clinique et / ou biologique ? Study of variability in response to aspirin and clopidogrel : Clinical and / or biological resistance ?

M. Samama, I. Elalamy, M.-M. Samamaa, 2009 .

Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina *

M. Samama, G. Gerotziafas, K. Zervas, 2003, British journal of haematology.

Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).

M. Samama, G. Gerotziafas, L. Bara, 1994, Haemostasis.

Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated factor VII.

H. Prydz, G. Mariani, F. Bernardi, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Biochemistry and clinical pharmacology of new anticoagulant agents

M. Samama, M. Horellou, I. Elalamy, 2002, Pathophysiology of Haemostasis and Thrombosis.

Laboratory monitoring of oral anticoagulant therapy.

M. Samama, L. Poller, 1994, Clinics in laboratory medicine.

Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation

G. Offenstadt, M. Samama, M. Wolf, 2012, Thrombosis and Haemostasis.

Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?

M. Samama, Sadia Meddahi, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Factor VII activation and menopausal status.

L. Guize, C. Bonithon-Kopp, M. Samama, 1990, Thrombosis research.

Laboratory assessment of new anticoagulants

M. Samama, C. Guinet, 2011, Clinical chemistry and laboratory medicine.

New heparin-like insoluble materials: Part I

M. Samama, L. Bara, J. Jozefonvicz, 2006, Annals of Biomedical Engineering.

Interactions of anticoagulant insoluble modified polystyrene resins with plasmatic proteins.

M. Samama, M. Jozefowicz, L. Bara, 1982, Thrombosis research.

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

M. Samama, J. Mendell, L. Le Flem, 2012, Thrombosis research.

The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.

M. Samama, 2011, Thrombosis research.

Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.

F. Depasse, M. Samama, S. Heptinstall, 2010, Thrombosis research.

concentrations and risk of myocardial infarction. The ECTIM Study Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen

D. Arveiler, G. Luc, F. Cambien, 2011 .

Factor VII activation and oral contraceptives.

L. Guize, M. Samama, P. Scarabin, 1993, Thrombosis research.

FURTHER EVIDENCE THAT ACTIVATED FACTOR VII IS RELATED TO PLASMA LIPIDS

M. Samama, P. Scarabin, L. Bara, 1985, British journal of haematology.

Anticoagulation: The Old and the New

M. Samama, A. Kher, 1998 .

Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis

M. Samama, Y. Lanson, P. Bernard, 1988, The British journal of surgery.

Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration.

M. Samama, L. Bara, E. Billaud, 1985, Thrombosis research.

Newer anticoagulants in 2009

M. Samama, G. Gerotziafas, 2009, Journal of Thrombosis and Thrombolysis.

CONGENITAL FACTOR VII DEFICIENCY AND CEREBROVASCULAR STROKE

M. Samama, J. Lefrère, M. Horellou, 1985, The Lancet.

Prognostic factors for retinal vein occlusion: prospective study of 175 cases.

G. Coscas, M. Samama, A. Chabanel, 1996, Ophthalmology.

DETECTION OF FIBRINOGEN ABNORMALITY IN DYSFIBRINOGENEMIA SPECIAL REPORT ON FIBRINOGEN METZ CHARACTERIZED BY AN AMINO ACID SUBSTITUTION LOCATED AT THE PEPTIDE BOND CLEAVED BY THROMBIN.

C. Southan, J. Soria, C. Soria, 1982 .

Prevention and treatment of venous thromboembolism - International Consensus Statement (Guidelines according to scientific evidence)

A. Nicolaides, S. Goldhaber, V. Kakkar, 2006 .

Thrombosis and Pregnancy in Congenital Deficiencies in AT III, Protein C or Protein S: Study of 78 Women

M. Samama, T. Lecompte, J. Conard, 1990, Thrombosis and Haemostasis.

Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent

M. Samama, J. Fareed, W. Jeske, 2002, Expert opinion on investigational drugs.

On The Mechanism Of Inhibition Of Factor Viia By Synthetic Pentasaccharide, Low‐Molecular‐Weight Heparins And Unfractionated Heparin

M. Samama, G. Gerotziafas, 2000, British journal of haematology.

Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma.

M. Bloch, M. Samama, G. Gerotziafas, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

J. Hirsh, K. Bauer, M. Samama, 2008, Chest.

Expression of a Paternal History of Premature Myocardial Infarction on Fibrinogen, Factor VIIC and PAI-1 in European Offspring - The EARS Study

L. Tiret, F. Cambien, V. Nicaud, 1994, Thrombosis and Haemostasis.

Do new oral anticoagulants require laboratory monitoring? The clinician point of view.

M. Samama, L. Le Flem, C. Guinet, 2012, Thrombosis research.

Comparative Pharmacokinetics of LMWHs

M. Samama, G. Gerotziafas, M. Samama, 2000, Seminars in thrombosis and hemostasis.

Thrombolytic therapy in myocardial infarction: Are fibrinolytic drugs comparable, and similarly effective?

M. Samama, E. Szwarcer, 1985 .

Haemostatic Variables and Menopausal Status: Influence of Hormone Replacement Therapy

L. Guize, C. Bonithon-Kopp, M. Samama, 1993, Thrombosis and Haemostasis.

Applying risk assessment models in general surgery: effective risk stratification.

M. Samama, 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence.

A. Nicolaides, S. Goldhaber, K. Myers, 2001, International angiology : a journal of the International Union of Angiology.

The Problem and the Need for Prevention

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays

M. Samama, J. Ansell, T. Spiro, 2013, Annals of medicine.

Prevention of Deep Vein Thrombosis after Hip Replacement

H. Büller, M. Samama, J. Barrê, 1999, Thrombosis and Haemostasis.

Which test to use to measure the anticoagulant effect of rivaroxaban: the anti‐factor Xa assay

M. Samama, M. Samama, 2013, Journal of thrombosis and haemostasis : JTH.

Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study.

A. Turpie, A. Cohen, M. Samama, 2004, Archives of pathology & laboratory medicine.

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life‐threatening hemorrhage

E. Hatjiharissi, M. Samama, M. Papaioannou, 2002, American journal of hematology.

Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group.

M. Samama, A. Leizorovicz, L. Bara, 1992, Thrombosis research.

Pharmacokinetics of low molecular weight heparins.

M. Samama, L. Bara, 1990, Acta chirurgica Scandinavica. Supplementum.

Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.

A. Carpentier, M. Samama, E. Terrier, 1986, Haemostasis.

Pregnancy‐associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone

M. Samama, M. Horellou, I. Elalamy, 2003, British journal of haematology.

Heritable Thrombophilia and Pregnancy Associated Thrombosis.

M. Samama, M. Horellou, I. Elalamy, 2002, Turkish journal of haematology : official journal of Turkish Society of Haematology.

Management of Pregnancy in Women with Thrombophilia

M. Samama, M. Horellou, J. Conard, 1999, Pathophysiology of Haemostasis and Thrombosis.

[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].

C. Samama, S. Susen, P. Fontana, 2013, Annales francaises d'anesthesie et de reanimation.

Prophylaxis for venous thrombosis in medical and surgical patients

M. Samama, Gregory Gerotziafas, G. Gerotziafas, 2006 .

Gynecology and Obstetrics

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[New antithrombotic agents].

M. Samama, A. Kereveur, Samama Mm, 1995, Presse medicale.

Does ambulation modify venous thromboembolism risk in acutely ill medical patients?

A. Amin, M. Samama, F. Girard, 2010, Thrombosis and Haemostasis.

Prevention of Postthrombotic Syndrome

G. Raskob, A. Nicolaides, M. Griffin, 2013 .

Choice of low molecular weight heparins

M. Samama, 2003, Journal of thrombosis and haemostasis : JTH.

Anti Xa activity and prothrombinase inhibition in patients treated with two different doses of enoxaparin in gynecologic surgery.

M. Samama, P. Girard, J. Conard, 1991, Thrombosis research. Supplement.

Assessment of treatment strategy in high-risk surgical patients.

M. Samama, 2000, Seminars in hematology.

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

F. Depasse, J. Amiral, M. Samama, 2010, Thrombosis and Haemostasis.

Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.

G. Helft, F. Beygui, M. Samama, 1998, Catheterization and cardiovascular diagnosis.

[Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].

F. Depasse, M. Samama, J. Conard, 2010, Annales pharmaceutiques francaises.

Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence.

A. Nicolaides, P. Prandoni, K. Myers, 2005, International angiology : a journal of the International Union of Angiology.

Thrombolytic properties of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (scu-PA) in vitro: Absence of synergy as demonstrated by two quantitative analytical methods

M. Samama, J. Frétault, J. Coursaget, 1989 .

The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement.

D. Warwick, M. Samama, 2000, The Journal of bone and joint surgery. British volume.

Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration.

M. Samama, J. Dawes, L. Bara, 1986, Haemostasis.

Changes in Haemostatic Variables Induced by Oral Contraceptives Containing 50 μg or 30 μg Oestrogen: Absence of Dose-dependent Effect on PAI-1 Activity

L. Guize, M. Samama, P. Scarabin, 1995, Thrombosis and Haemostasis.

Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.

M. Bloch, A. Uzan, M. Samama, 1993, Thrombosis research.

Primary and secondary prophylaxis of venous thromboembolism with low‐molecular‐weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists

M. Samama, A. Kher, M. Samama, 2005, Journal of thrombosis and haemostasis : JTH.

Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency

J. Griffin, A. Gruber, K. Bauer, 1993 .

Congenital protein C deficiency and thrombotic disease in nine French families.

M. Samama, R. Bertina, J. Conard, 1984, British medical journal.

Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion.

M. Samama, A. K. Vine, 1997, American journal of ophthalmology.

[Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress].

M. Samama, 2012, Presse medicale.

Degradation of fibrinogen by tissue plasminogen activator. Consequences for fibrin polymerization.

J. Soria, C. Soria, M. Samama, 1990, Thrombosis research. Supplement.

Persistent Heparin Induced Thrombocytopenia Despite Therapy with Low Molecular Weight Heparin

A. Bernadou, M. Samama, G. D. Di Maria, 1984, Thrombosis and Haemostasis.

An animal model for the evaluation of graft thrombosis in the acute phase on carbon-lined PTFE prosthesis

M. Bloch, D. Agostini, M. Samama, 1994, The International journal of artificial organs.

Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity.

M. Samama, J. Fareed, M. Petitou, 1988, Thrombosis research.

Prevention of venous thromboembolism after surgery: A review of enoxaparin

J. Hirsh, G. Lowe, A. Berstad, 1992, The British journal of surgery.

PREGNANCY AND CONGENITAL DEFICIENCY IN ANTITHROMBIN III OR PROTEIN C

M. Samama, J. Conard, M. Horellou, 1987, Thrombosis and Haemostasis.

Spontaneous platelet aggregation in heparin-treated patients.

M. Samama, J. Conard, C. Lecrubier, 1984, Acta haematologica.

Effect of Standard Heparin and a Low Molecular Weight Heparin on Thrombolytic and Fibrinolytic Activity of Single-Chain Urokinase Plasminogen Activator In Vitro

M. Samama, D. Lourenço, A. Dosne, 1989, Thrombosis and Haemostasis.

Miscellaneous: Dextran, Dermatan Sulfate, Low Molecular Weight Heparinoids (Org 10172), Pentosan Polysulfate (Sp54), Defibrinating Agents (Ancrod And Reptilase)

H. Kwaan, M. Samama, P. Desnoyers, 2019, Clinical Thrombosis.

Damad study research group : Effect of age on ADP-induced platelet aggregation in diabetic and non-diabetic subjects

M. Samama, P. Scarabin, 1981 .

Constitutional Thrombocytopathy with Subnormal Response to Thromboxane A2

B. Vargaftig, M. Lagarde, M. Chignard, 1981, British journal of haematology.

Fibrinogen and platelet aggregation. Role of the glycopeptidic part and of the fibrinopeptide B. Description of a new technique of fibrinoglycopeptide isolation.

J. Soria, C. Soria, O. Bertrand, 1978, Biochemical and biophysical research communications.

Hypofibrinolysis and venous thrombosis

M. Samama, 1992 .

Critical Care Medical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis.

Treatment of deep vein thrombosis (DVT) with low molecular weight heparins (LMWH).

M. Samama, 1992, Advances in experimental medicine and biology.

Specific Anti-Xa Activity of LMWH (Kabi 2165, CY216 PK 10169) Against the First International Standard of LMWH: A Collaborative Study

M. Samama, M. Dautzenberg, L. Bara, 1990, Thrombosis and Haemostasis.

Effects of long term administration of ticlopidine on platelet function and hemostatic variables.

M. Bousser, M. Samama, M. Horellou, 1980, Thrombosis research.

Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors.

G. Coscas, M. Samama, A. Chabanel, 1994, Ophthalmology.

Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of post‐thrombotic treatment

M. Samama, A. Chabanel, M. Horellou, 1994, British journal of haematology.

Double-Blind Trial of the Efficacy of Troxerutin in Chronic Venous Insufficiency

M. Samama, A. Chabanel, F. Vin, 1994 .

Increased red blood cell aggregation in retinal vein occlusion

G. Coscas, M. Samama, A. Chabanel, 1990, British journal of haematology.

Overall study of the in vitro plasma clotting system in an invertebrate, Liocarcinus puber (Crustacea Decapoda): considerations on the structure of the Crustacea plasma fibrinogen in relation to evolution.

M. Samama, C. Montmory, D. Vergoz, 1989, Journal of invertebrate pathology.

Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease

M. Samama, I. Elalamy, Z. Dridi, 2009, Journal of Thrombosis and Thrombolysis.

Evaluation of a method to assess plasma viscosity: the falling ball viscometer

M. Samama, A. Chabanel, 1994 .

Study of acquired dysfibrinogenaemia in liver disease.

J. Soria, C. Soria, M. Samama, 1980, Thrombosis research.

[Plasminogen determination, using a chromogenic tripeptidic substrate (author's transl)].

J. Soria, C. Soria, M. Samama, 1976, Pathologie-biologie.

Prevention of Deep Vein Thrombosis after Hip Replacement

H. Büller, M. Samama, A. Lensing, 2017 .

Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: A report of four patients

M. Samama, J. Conard, J. Audouin, 1991, American journal of hematology.

Conformational change in fibrinogen induced by adsorption to a surface

J. Soria, C. Soria, A. Aurengo, 1985 .

Antiplatelet Effects of the Addition of Acetylsalicylic Acid 40 Mg Daily to Ticlopidine in Human Healthy Volunteers

J. Maffrand, M. Samama, T. Lecompte, 1997 .

Risk of thromboembolism in relation to an in-vitro fertilization programme: three case reports.

M. Samama, J. hugues, M. Aurousseau, 1995, Human reproduction.

Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood.

M. Bloch, M. Samama, G. Gerotziafas, 1996, Thrombosis research.

Circulating platelet-leukocyte aggregates: a marker of microvascular injury in diabetic patients.

M. Samama, F. Elgrably, I. Elalamy, 2008, Thrombosis research.

Familial dysfibrinogenemia and thrombophilia. Structural defects and impaired fibrinolysis

M. Samama, F. Haverkate, 1994 .

[Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin].

M. Samama, C. de Gennes, P. Chigot, 1996, Journal des maladies vasculaires.

Familial and constitutional bleeding disorder due to platelet cyclo‐oxygenase deficiency

B. Vargaftig, M. Chignard, F. Fouque, 1983, American journal of hematology.

Suitability of Chromogenic Anti-Factor Xa Methods to Measure Rivaroxaban in Human Plasma

F. Depasse, J. Amiral, M. Samama, 2009 .

[Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].

M. Samama, I. Gouin, A. Kher, 2000, Annales de biologie clinique.

In vitro effect on heptest® of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities

M. Samama, L. Bara, J. Mardiguian, 1990 .

In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities.

M. Samama, L. Bara, J. Mardiguian, 1990, Thrombosis research.

The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement.

D. Warwick, M. Samama, F. Orth, 2000, The Journal of bone and joint surgery. British volume.

Title Page / Table of Contents / Preface

F. Sofi, R. Abbate, P. Morange, 2003, Pathophysiology of Haemostasis and Thrombosis.

Structure, Pharmacology, and Clinical Use of Antifibrinolytic Agents

C. Samama, W. Dietrich, M. Samama, 2001 .

[THE ROLE OF EPSILON-AMINOCAPROIC ACID IN FIBRINOLYTIC STATES].

M. Samama, G. Bilski‐Pasquier, G. Marchal, 1964, Revista clínica española (Ed. impresa).

Compared activity of human, rat and rabbit plasma tissue factor pathway inhibitors.

M. Samama, L. Bara, D. Zitoun, 1993, Thrombosis research.

The significance of endothelial heterogeneity in thrombosis and hemostasis.

H. Kwaan, M. Samama, 2010, Seminars in thrombosis and hemostasis.

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

T. Baglin, M. Samama, J. Weitz, 2012, Chest.

Heterogeneity of synthetic factor Xa inhibitors.

M. Samama, G. Gerotziafas, 2005, Current pharmaceutical design.

Fibrinolysis and Thrombosis: Pathways and Inhibitors

M. Samama, 1981 .

[DISSOCIATED EFFECTS OF A NEW ANTIFIBRINOLYTIC AGENT (EPSILON-AMINOCAPROIC ACID) INJECTED "IN VIVO", ON "IN VITRO" FIBRINOLYSIS TESTS].

M. Samama, C. Dubost, J. Yver, 1963, La Presse medicale.

[The new heparins].

M. Samama, 1986, Presse medicale.

[Study of coagulation and hemostasis in 74 cases of cirrhosis].

M. Samama, G. Marchal, R. Prost, 1960, Le Sang.

Urokinase I and II Activity

M. Samama, B. Cazenave, A. Otero, 1978, Thrombosis and Haemostasis.

Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits.

M. Bloch, M. Samama, L. Bara, 1994, Thrombosis research.

A comparative study of recombinant hirudin and standard heparin in the Wessler model.

M. Bloch, M. Samama, L. Bara, 1992, Thrombosis research.

The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.

M. Samama, J. Fareed, M. Petitou, 1988, Thrombosis research.

Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay

F. Depasse, M. Samama, I. Elalamy, 2005, Thrombosis journal.

The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation

F. Depasse, M. Samama, I. Elalamy, 2004, Thrombosis and Haemostasis.

Coronary Stenting in a Hemophilic Patient

G. Helft, M. Samama, A. Vacheron, 1997, Thrombosis and Haemostasis.

From pharmacologic studies to the improvement of thromboprophylaxis

M. Samama, G. Gerotziafas, 2003 .

Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenaemia (fibrinogen Malmoe)

J. Soria, C. Soria, D. Bergqvist, 1985, British journal of haematology.

A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.

A. Turpie, A. Cohen, M. Samama, 1999, The New England journal of medicine.

Patients With Cancer

S. Kakkos, P. Prandoni, G. Raskob, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Tumour necrosis factor α stimulates the production of pro-urokinase from the A549 lung carcinoma cell line

M. Samama, R. Beaupain, A. Dosne, 1990 .

312 Cultured A549 lung carcinoma cells release sc-UPA

M. Samama, A. Dosne, F. Lutcher, 1988 .

Defective thrombolysis due to collagen incorporation in fibrin clots.

J. Soria, C. Soria, M. Samama, 1988, Thrombosis research. Supplement.

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

J. Hirsh, K. Bauer, M. Samama, 2008, Chest.

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

J. Eikelboom, M. Samama, J. Weitz, 2012, Chest.

Antithrombotic therapy for venous thromboembolic disease.

G. Agnelli, V. Tapson, R. Hull, 1998, Chest.

The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile

M. Samama, I. Elalamy, G. Gerotziafas, 2006, Thrombosis and Haemostasis.

Red cell aggregability increases with the severity of venous insufficiency.

M. Samama, A. Chabanel, F. Zuccarelli, 1995, International angiology : a journal of the International Union of Angiology.

Analysis of a fibrin formation abnormality in a case of multiple myeloma.

J. Soria, C. Soria, M. Samama, 2009, Scandinavian journal of haematology.

Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta- fibrin)

J. Soria, C. Soria, M. Samama, 1987 .

Prevention and Treatment of Venous Thromboembolism

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

At III content and antithrombin in activity in oestrogen-progestogen and progestogen-only treated women.

M. Samama, M. Horellou, J. Conard, 1980, Thrombosis research.

Fibrinogen Haifa: Fibrinogen Variant with Absence of Protective Effect of Calcium on Plasmin Degradation of Gamma Chains

J. Soria, C. Soria, A. Henschen, 1987, Thrombosis and Haemostasis.

The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions.

M. Samama, A. K. Vine, M. Samama, 1993, Survey of ophthalmology.

Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.

H. Büller, P. Leyvraz, M. Samama, 1991, BMJ.

The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg

M. Samama, A. Frydman, L. Bara, 1988, Journal of clinical pharmacology.

Heterogeneous mechanisms responsible for reduced fibrinolytic capacity in patients with a history of venous thrombosis

M. Samama, J. Conard, S. Combe, 1994 .

The Amidolytic Activity of the SK-Plasminogen Complex Is Enhanced by a Potentiator which Is Generated in the Presence of Vascular Plasminogen Activator - Role of Fibrin Degradation Products

J. Soria, C. Soria, O. Bertrand, 1982, Thrombosis and Haemostasis.

The Significance of Several Coagulation Tests in the Evaluation of the Risk of Bleeding

M. Samama, 1984 .

In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile

M. Samama, I. Elalamy, G. Gerotziafas, 2004, Thrombosis and Haemostasis.

Laboratory Techniques in Thrombosis – A Manual, 2nd Revised Edition of ECAT Assay Procedures

M. Samama, 2000 .

Bovine or human thrombin in amidolytic at III assays. Influence of heparin cofactor II.

M. Samama, J. Conard, L. Bara, 1986, Thrombosis research.

Antithrombin III in Contraceptive Treatments with Oestroprogestagens or Progestagen -Only Pills

M. Samama, M. Horellou, J. Conard, 1979, Thrombosis and Haemostasis.

Incidence of thromboembolism in association with congenital disorders in coagulation and fibrinolysis.

M. Samama, J. Conard, M. Horellou, 1988, Acta chirurgica Scandinavica. Supplementum.

EFFECT OF ASPIRIN AND ASPIRIN COMBINED WITH DIPYRIDAMOLE IN EARLY DIABETIC RETINOPATHY

C. Baudoin, M. Samama, 1987, Thrombosis and Haemostasis.

Markers of fibrinogen derivatives used in clinical investigation.

J. Soria, C. Soria, M. Samama, 1985, Seminars in thrombosis and hemostasis.

The Need for Standardization of Low Molecular Weight Heparin (LMWH)

M. Samama, L. Bara, 1986, Thrombosis and Haemostasis.

Pro- and anti-angiogenic agents.

S. Mousa, A. Bridoux, S. Mousa, 2012, Journal des maladies vasculaires.

Comparative Study of the Activity of High and Low Molecular Weight Urokinase in the Presence of Fibrin

M. Samama, O. Matsuo, H. Lijnen, 1982, Thrombosis and Haemostasis.

Effect of Agents which Modify Platelet Aggregation and/or Coagulation on Experimental Platelet Embolism and Intravascular Coagulation

M. Bousser, M. Samama, L. Bara, 1977 .

The Thrombophilic State in Cancer Patients

M. Samama, I. Gouin-Thibault, A. Achkar, 2001, Acta Haematologica.

New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

J. Hirsh, M. Samama, J. Weitz, 2008, Chest.

[THE ALDRICH SYNDROME (FAMILIAL THROMBOPENIC PURPURA, ECZEMA, RECURRING INFECTIONS)].

M. Samama, M. Bonnet-Gajdos, G. Bilski‐Pasquier, 1963, La Presse medicale.

Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th New Antithrombotic Drugs : Antithrombotic

J. Eikelboom, M. Samama, J. Weitz, 2012 .

Pharmacology and laboratory testing of the oral Xa inhibitors.

C. Samama, M. Samama, Sadia Meddahi, 2014, Clinics in laboratory medicine.

Thrombolytic Therapy: Future Issues

M. Samama, J. Acar, M. Samama, 1995, Thrombosis and Haemostasis.

Fibrinogen Troyes - Fibrinogen Metz

J. Soria, C. Soria, M. Samama, 1972, Thrombosis and Haemostasis.

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

M. Samama, F. Lee, J. Mendell, 2013, Journal of cardiovascular pharmacology.

Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment

M. Samama, 2011, Drugs & aging.

[Is Behçet's disease associated with characteristic abnormalities of coagulation and fibrinolysis? Apropos of 70 case reports].

D. Fassin, M. Samama, B. Wechsler, 1988, Journal des maladies vasculaires.

Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels

M. Samama, D. Hoppensteadt, J. Fareed, 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Orthopedic Surgery and Trauma

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Structure Abnormality Of Fibrinogen Metz And Its Relationship To The Clotting Defect

C. Southan, J. Soria, C. Soria, 1981, Thrombosis and Haemostasis.

Clot-promoting and platelet-aggregating effects of fatty acids.

M. Samama, R. J. Prost-Dvojaković, 1973, Haemostasis.

Effects of saturated and unsaturated fatty acids on blood platelet aggregation in vitro and after injection into rabbits.

M. Samama, L. Bara, R. Prost, 1972, Acta Universitatis Carolinae. Medica. Monographia.

INCREASED SENSITIVITY OF PLATELETS TO ADRENALINE IN HUMAN MYOTONIC DYSTROPHY

M. Bousser, M. Samama, J. Conard, 1975, The Lancet.

Clinical Studies with Anticoagulants to Improve Survival in Cancer Patients

Mohamed Hatmi, M. Samama, I. Elalamy, 2007, Pathophysiology of Haemostasis and Thrombosis.

Rapid Aequorin Loading into Platelets in the Presence of DMSO - Characteristics of the Responses (Changes in Light Transmission and in Calcium) to Various Agonists

M. Samama, T. Lecompte, R. Favier, 1991, Thrombosis and Haemostasis.

Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations.

H. Prydz, M. Pinotti, G. Mariani, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Is factor VII activation in pregnant women relevant to fetal growth retardation?

M. Samama, P. Blot, P. Scarabin, 1987, Thrombosis research.

An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.

M. Samama, M. Samama, 2000, Archives of internal medicine.

Ultraviolet irradiation of platelet concentrates: In Vitro and In Vivo preclinical evaluation

M. Samama, G. Andreu, J. Klaren, 1990 .

The heparin management test: a new device for monitoring anticoagulation during coronary intervention.

S. Chokron, A. Zaman, G. Helft, 1999, Thrombosis research.

Severe Protein C Deficiency in Congenital Thrombotic Disease – Description of an Immunoenzymological Assay for Protein C Determination

J. Soria, C. Soria, W. Kisiel, 1985, Thrombosis and Haemostasis.

Determination of fibrinogen degradation products using antifibrinogen serum and anti-fragment E serum

J. Soria, C. Soria, M. Samama, 1973 .

Importance of plasminogen activator inhibitor type 1 (PAI-1) for preventing single chain urokinase plasminogen activator (scu-PA) conversion into two chain urokinase plasminogen activator (tcu-PA) in plasma in vitro.

M. Samama, A. Dosne, F. Dubor, 1991, Thrombosis research.

[Randiomized trial of a new platelet anti-aggregant agent: ticlopidine].

M. Bousser, M. Samama, J. Conard, 1977, Therapie.

Anticoagulant drugs: an update

H. Kwaan, M. Samama, 2004, Expert review of cardiovascular therapy.

Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction.

J. Soria, C. Soria, M. Samama, 1987, Seminars in thrombosis and hemostasis.

Laboratory control of thrombolytic treatment of myocardial infarction with rt-PA

M. Samama, 1993 .

[Congenital and familial dysfibrinogenemia without hemorrhagic tendancy].

J. Soria, C. Soria, M. Samama, 1969, Nouvelle revue francaise d'hematologie.

Prothrombotic states in retinal artery and vein occlusions

M. Samama, A. K. Vine, 2002 .

General, Vascular, Bariatric, and Plastic Surgical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis.

Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.

A. Turpie, A. Cohen, M. Samama, 2004, Archives of internal medicine.

Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study

R. Yusen, A. Turpie, M. Monreal, 2006, Journal of Thrombosis and Thrombolysis.

[Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians].

M. Samama, M. Horellou, J. Conard, 2009, Journal des maladies vasculaires.

Prevention and treatment of venous thromboembolism--International Consensus Statement.

P Prandoni, G D Lowe, D Bergqvist, 2013, International angiology : a journal of the International Union of Angiology.

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study

A. Turpie, A. Cohen, M. Samama, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin.

G. Coscas, M. Samama, A. Chabanel, 1994, American journal of ophthalmology.

[Thrombotic thrombopenic purpura associated with Hodgkin's disease].

J. Diebold, M. Tulliez, M. Samama, 1983, Nouvelle revue francaise d'hematologie.

Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions.

M. Samama, J. Fareed, J. Walenga, 1985, Seminars in thrombosis and hemostasis.

[Malignant atrophic papulosis with insufficiency of blood fibrinolysis].

M. Samama, J. Camilleri, C. Foix, 1982, Annales de dermatologie et de venereologie.

Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients.

M. Samama, M. Horellou, M. Boffa, 1988, Journal of medicine.

Standardization of platelet counts--problems and pitfalls.

M. Samama, C. Capelle, 2009, Scandinavian journal of haematology. Supplementum.

Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

Elisabeth Perzborn, F. Depasse, M. Samama, 2010, Thrombosis and Haemostasis.

Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin.

M. Samama, L. Bara, E. Billaud, 1985, Seminars in Thrombosis and Hemostasis.

[Current biological surveillance of oral anticoagulant treatment].

G. Helft, M. Samama, A. Vacheron, 1995, Archives des maladies du coeur et des vaisseaux.

Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta-fibrin).

J. Soria, C. Soria, M. Samama, 1987, Blood.

Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).

M. Samama, G. Gerotziafas, 2003, Thrombosis research.

Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosis

P. Reitsma, M. Samama, R. Bertina, 1992, The Lancet.

INTRAVENOUS LABETALOL FOR TREATMENT OF POSTOPERATIVE HYPERTENSIONEFFECTS ON HEMODYNAMICS AND LEFT VENTRICULAR FUNCTION

P. Coriat, G. Godet, M. Samama, 1988 .

Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study

R. Yusen, A. Turpie, M. Monreal, 2013, Stroke.

Risk assessment models for thromboprophylaxis of medical patients.

M. Samama, M. Horellou, J. Conard, 2012, Thrombosis research.

Urologic Surgery

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

In vitro interaction of the pentasaccharide idraparinux (SanOrg 34006) with unfractionated heparin

F. Maris, M. Samama, I. Gouin-Thibault, 2003, Journal of thrombosis and haemostasis : JTH.

Cost-Effectiveness of Prevention and Treatment of VTE

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Prevention of thromboembolic disease in general surgery with enoxaparin.

M. Samama, S. Combe-Tamzali, 1989, British journal of clinical practice. Supplement.

Ticlopidine and Platelet Function

M. Samama, T. Lecompte, C. Lecrubier, 1986, Thrombosis and Haemostasis.

[Platelets and atherosclerosis].

M. Bousser, M. Samama, 1973, Coeur et medecine interne.

In vitro effect of melagatran and lepirudin on clot-bound thrombin.

M. Samama, I. Elalamy, J. Lebrazi, 2003, Thrombosis Research.

Platelet-associated fibrinogen: Conformational change of fibrinogen induced by its adsorption to platelet-surface

J. Soria, C. Soria, A. Bernadou, 1986 .

A fatal low‐molecular‐weight heparin‐associated thrombocytopenia after hip surgery: possible usefulness of PF4‐heparin ELISA test

M. Samama, I. Elalamy, J. Marie, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.

M. Samama, J. Fareed, W. Jeske, 2002, Turkish journal of haematology : official journal of Turkish Society of Haematology.

Deep vein thrombosis of inferior limbs: are thrombolytic agents superior to heparin?

M. Samama, 1987, Seminars in Thrombosis and Hemostasis.

IS INHALED NITRIC OXIDE ABLE TO REVERSE ALMITRINE-INDUCED PULMONARY HYPERTENSION IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME?

L. Puybasset, P. Kalfon, J. Rouby, 1994 .

Inherited thrombophilia and gestational venous thromboembolism.

M. Samama, M. Horellou, J. Conard, 2003, Seminars in thrombosis and hemostasis.

Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and a low molecular-weight heparin.

M. Samama, A. Bendetowicz, A. Dosne, 1988, Thrombosis research.

Prevention ofdeepveinthrombosis after hipreplacement: randomised comparison between unfractionated heparin andlow molecular weight heparin

M. Samama, M. Postel, M. Vandenbroek, 1991 .

Platelet and red-cell fragments in thrombocytopenia.

M. Samama, M. Boisseau, R. Le Menn, 1978, New England Journal of Medicine.

Vitamin K metabolism in a patient resistant to vitamin K antagonists.

M. Trossaërt, M. Samama, F. Parent, 1997, Haemostasis.

[Platelet volume in essential thrombopenia].

M. Samama, R. Le Menn, R. J. Prost-Dvojaković, 1978, Nouvelle revue francaise d'hematologie.

Development of a Synthetic Heparin Pentasaccharide as an Antithrombotic Drug

M. Samama, J. Fareed, W. Jeske, 2002 .

[Thrombolysis by streptokinase (experimental and clinical study)].

M. Samama, P. Desnoyers, L. Bara, 1969, Archives des maladies du coeur et des vaisseaux.

Discriminant study of platelet volume indices in the etiological diagnosis of thrombocytopenia.

M. Samama, M. Tirmarche, M. Hotchen, 1984, Acta haematologica.

Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma

F. Depasse, M. Samama, Meyer M Samama, 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

In spite of elevated plasma fibrinogen, red blood cell aggregation is not increased in smokers

M. Samama, A. Chabanel, G. Andreu, 1992 .

[Platelet collection by apheresis with reduced use of citrate: quantitative and qualitative evaluation of three protocols].

M. Samama, G. Andreu, C. Lecrubier, 1995, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[A century of progress. From biology to antithrombotic agents].

M. Samama, 2001, Journal des maladies vasculaires.

Combined Modalities in Surgical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[Thrombolytic agents and acute pulmonary emboli. Study of 28 cases treated by streptokinase or urokinase-heparin].

M. Samama, R. Bénaim, J. Maury, 1978, Coeur et medecine interne.

Risk assessment models for thromboprophylaxis of medical patients.

M. Samama, M. Horellou, J. Conard, 2012, Thrombosis research.

Clinical Thrombosis

H. Kwaan, M. Samama, 2019 .

[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].

M. Samama, M. Samama, S. Meddahi, 2014, Journal des maladies vasculaires.

Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment

M. Samama, 2011, Drugs & aging.

Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy.

M. Samama, J. Seghatchian, 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

J. Hirsh, M. Samama, J. Weitz, 2008, Chest.

The fibrinolytic system in patients with congenital protein C deficiency.

M. Samama, R. Bertina, J. Conard, 1984, Thrombosis research.

Effects of the synthetic fibrinolytic agents ortho-thymotic acid and S-1623 on the reaction between human plasmin and antiplasmin.

B. Wiman, M. Samama, D. Collen, 1978, Thrombosis research.

Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients

R. Yusen, A. Turpie, M. Monreal, 2013, Thrombosis and Haemostasis.

[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].

M. Samama, M. Samama, S. Meddahi, 2011, Journal des maladies vasculaires.

[Anomalies of platelet aggregation during Waldenström's disease. (Apropos of 3 cases)].

M. Samama, J. Bousser, R. Prost, 1966, Nouvelle revue francaise d'hematologie.